ADMA vs. ACAD, AKRO, ALLO, FGEN, SMMT, ITCI, GMAB, RDY, MRNA, and RGC
Should you be buying ADMA Biologics stock or one of its competitors? The main competitors of ADMA Biologics include ACADIA Pharmaceuticals (ACAD), Akero Therapeutics (AKRO), Allogene Therapeutics (ALLO), FibroGen (FGEN), Summit Therapeutics (SMMT), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Moderna (MRNA), and Regencell Bioscience (RGC). These companies are all part of the "pharmaceutical products" industry.
ADMA Biologics vs. Its Competitors
ADMA Biologics (NASDAQ:ADMA) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both mid-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, media sentiment, institutional ownership, dividends and analyst recommendations.
ADMA Biologics currently has a consensus price target of $27.67, suggesting a potential upside of 49.47%. ACADIA Pharmaceuticals has a consensus price target of $27.88, suggesting a potential upside of 32.86%. Given ADMA Biologics' stronger consensus rating and higher probable upside, equities analysts clearly believe ADMA Biologics is more favorable than ACADIA Pharmaceuticals.
ACADIA Pharmaceuticals has higher revenue and earnings than ADMA Biologics. ACADIA Pharmaceuticals is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.
ADMA Biologics has a net margin of 45.01% compared to ACADIA Pharmaceuticals' net margin of 22.97%. ADMA Biologics' return on equity of 47.16% beat ACADIA Pharmaceuticals' return on equity.
ADMA Biologics has a beta of 0.43, suggesting that its share price is 57% less volatile than the S&P 500. Comparatively, ACADIA Pharmaceuticals has a beta of 0.64, suggesting that its share price is 36% less volatile than the S&P 500.
75.7% of ADMA Biologics shares are owned by institutional investors. Comparatively, 96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. 3.5% of ADMA Biologics shares are owned by insiders. Comparatively, 26.5% of ACADIA Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
In the previous week, ACADIA Pharmaceuticals had 2 more articles in the media than ADMA Biologics. MarketBeat recorded 7 mentions for ACADIA Pharmaceuticals and 5 mentions for ADMA Biologics. ADMA Biologics' average media sentiment score of 1.58 beat ACADIA Pharmaceuticals' score of 1.19 indicating that ADMA Biologics is being referred to more favorably in the media.
Summary
ADMA Biologics and ACADIA Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.
Get ADMA Biologics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ADMA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ADMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
ADMA Biologics Competitors List
Related Companies and Tools
This page (NASDAQ:ADMA) was last updated on 7/11/2025 by MarketBeat.com Staff